BR0111301A - Cicloexilaminas bicìclicas e seu uso como antagonistas de receptor de nmda - Google Patents
Cicloexilaminas bicìclicas e seu uso como antagonistas de receptor de nmdaInfo
- Publication number
- BR0111301A BR0111301A BR0111301-1A BR0111301A BR0111301A BR 0111301 A BR0111301 A BR 0111301A BR 0111301 A BR0111301 A BR 0111301A BR 0111301 A BR0111301 A BR 0111301A
- Authority
- BR
- Brazil
- Prior art keywords
- nmda receptor
- bicyclic
- cyclohexylamines
- receptor antagonists
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
"CICLOEXILAMINAS BICìCLICAS E SEU USO COMO ANTAGONISTAS DE RECEPTOR DE NMDA". São descritas cicloexilaminas bicíclicas substituídas de Fórmula (I) e seus sais farmaceuticamente aceitáveis. Os compostos são antagonistas de complexos de canal de receptor de NMDA úteis para tratamento de distúrbios vasculares cerebrais tal como, por exemplo, isquemia cerebral, parada cardíaca, derrame e doença de Parkinson. Os substituintes são definidos no relatório.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20824100P | 2000-05-31 | 2000-05-31 | |
PCT/US2001/014763 WO2001092239A1 (en) | 2000-05-31 | 2001-05-08 | Biciclic cyclohexylamines and their use as nmda receptor antogonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0111301A true BR0111301A (pt) | 2003-06-10 |
Family
ID=22773822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0111301-1A BR0111301A (pt) | 2000-05-31 | 2001-05-08 | Cicloexilaminas bicìclicas e seu uso como antagonistas de receptor de nmda |
Country Status (28)
Country | Link |
---|---|
US (1) | US6794402B2 (pt) |
EP (1) | EP1286975B1 (pt) |
JP (1) | JP2003535083A (pt) |
KR (1) | KR20030007797A (pt) |
CN (1) | CN1438996A (pt) |
AP (1) | AP2002002697A0 (pt) |
AT (1) | ATE302763T1 (pt) |
AU (1) | AU2001259618A1 (pt) |
BG (1) | BG107375A (pt) |
BR (1) | BR0111301A (pt) |
CA (1) | CA2409006A1 (pt) |
DE (1) | DE60112924T2 (pt) |
DZ (1) | DZ3361A1 (pt) |
EA (1) | EA200201158A1 (pt) |
EE (1) | EE200200667A (pt) |
ES (1) | ES2245985T3 (pt) |
HR (1) | HRP20021018A2 (pt) |
HU (1) | HUP0302323A2 (pt) |
IL (1) | IL153170A0 (pt) |
IS (1) | IS6625A (pt) |
MA (1) | MA26907A1 (pt) |
MX (1) | MXPA02011926A (pt) |
NO (1) | NO20025762L (pt) |
OA (1) | OA12275A (pt) |
PL (1) | PL359260A1 (pt) |
SK (1) | SK16632002A3 (pt) |
WO (1) | WO2001092239A1 (pt) |
ZA (1) | ZA200209325B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA02002749A (es) | 2001-03-27 | 2002-10-28 | Warner Lambert Co | Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato. |
GB0116594D0 (en) * | 2001-07-06 | 2001-08-29 | Cancer Res Ventures Ltd | Therapeutic compounds |
DE10210779A1 (de) * | 2002-03-12 | 2003-10-09 | Merck Patent Gmbh | Cyclische Amide |
JP4828823B2 (ja) * | 2002-06-07 | 2011-11-30 | コーティカル・ピーティーワイ・リミテッド | 治療用分子および方法−1 |
AU2002353193B2 (en) | 2002-12-20 | 2010-03-25 | Cancer Research Technology Limited | 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents |
WO2006071274A2 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
JP5270943B2 (ja) * | 2008-03-28 | 2013-08-21 | 大阪瓦斯株式会社 | フルオレン誘導体およびこのフルオレン誘導体を用いたアミノ基含有フルオレン誘導体の製造方法 |
US9345848B2 (en) | 2009-10-20 | 2016-05-24 | Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. | Dry powder inhaler |
WO2011092293A2 (en) * | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
CA2863006A1 (en) | 2012-01-27 | 2013-08-01 | National University Corporation University Of Toyama | Serine racemase inhibitor |
CN105001118A (zh) * | 2015-07-20 | 2015-10-28 | 湖南华腾制药有限公司 | 一种含碘叠氮化合物的制备方法 |
CN105153020A (zh) * | 2015-07-20 | 2015-12-16 | 湖南华腾制药有限公司 | 一种芳香叠氮化合物的制备方法 |
CN105152966A (zh) * | 2015-07-20 | 2015-12-16 | 湖南华腾制药有限公司 | 一种叠氮化合物的制备方法 |
CN105061254A (zh) * | 2015-07-20 | 2015-11-18 | 湖南华腾制药有限公司 | 一种含溴叠氮化合物的合成方法 |
WO2018033525A1 (en) * | 2016-08-16 | 2018-02-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Agonists or partial agonists of the histamine site of the nmda receptor for use in the treatment of central nervous system diseases |
CN107043335A (zh) * | 2017-05-31 | 2017-08-15 | 湖南华腾制药有限公司 | 一种2‑氟苯基叠氮化合物的制备方法 |
CN111315735B (zh) | 2017-09-04 | 2024-03-08 | C4医药公司 | 二氢苯并咪唑酮 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4438055A1 (de) | 1994-10-25 | 1996-05-02 | Thomae Gmbh Dr K | Ring- und N-substituierte N-Benzyl-cycloalkylamine, ihre Salze mit physiologisch verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel |
DE19812331A1 (de) | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
EP0982026B1 (en) * | 1998-08-18 | 2006-05-17 | F. Hoffmann-La Roche Ag | Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers |
-
2001
- 2001-05-08 HU HU0302323A patent/HUP0302323A2/hu unknown
- 2001-05-08 IL IL15317001A patent/IL153170A0/xx unknown
- 2001-05-08 ES ES01933173T patent/ES2245985T3/es not_active Expired - Lifetime
- 2001-05-08 JP JP2002500853A patent/JP2003535083A/ja active Pending
- 2001-05-08 OA OA1200200358A patent/OA12275A/en unknown
- 2001-05-08 EP EP01933173A patent/EP1286975B1/en not_active Expired - Lifetime
- 2001-05-08 CN CN01811676A patent/CN1438996A/zh active Pending
- 2001-05-08 AT AT01933173T patent/ATE302763T1/de not_active IP Right Cessation
- 2001-05-08 DE DE60112924T patent/DE60112924T2/de not_active Expired - Fee Related
- 2001-05-08 EE EEP200200667A patent/EE200200667A/xx unknown
- 2001-05-08 US US10/276,054 patent/US6794402B2/en not_active Expired - Fee Related
- 2001-05-08 PL PL01359260A patent/PL359260A1/xx not_active Application Discontinuation
- 2001-05-08 AU AU2001259618A patent/AU2001259618A1/en not_active Abandoned
- 2001-05-08 MX MXPA02011926A patent/MXPA02011926A/es active IP Right Grant
- 2001-05-08 BR BR0111301-1A patent/BR0111301A/pt not_active IP Right Cessation
- 2001-05-08 DZ DZ013361A patent/DZ3361A1/fr active
- 2001-05-08 KR KR1020027016301A patent/KR20030007797A/ko not_active Application Discontinuation
- 2001-05-08 CA CA002409006A patent/CA2409006A1/en not_active Abandoned
- 2001-05-08 SK SK1663-2002A patent/SK16632002A3/sk not_active Application Discontinuation
- 2001-05-08 EA EA200201158A patent/EA200201158A1/ru unknown
- 2001-05-08 WO PCT/US2001/014763 patent/WO2001092239A1/en active IP Right Grant
- 2001-05-08 AP APAP/P/2002/002697A patent/AP2002002697A0/en unknown
-
2002
- 2002-11-15 ZA ZA200209325A patent/ZA200209325B/en unknown
- 2002-11-18 IS IS6625A patent/IS6625A/is unknown
- 2002-11-27 MA MA26924A patent/MA26907A1/fr unknown
- 2002-11-29 NO NO20025762A patent/NO20025762L/no not_active Application Discontinuation
- 2002-12-11 BG BG107375A patent/BG107375A/bg unknown
- 2002-12-19 HR HR20021018A patent/HRP20021018A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2001259618A1 (en) | 2001-12-11 |
ES2245985T3 (es) | 2006-02-01 |
DZ3361A1 (fr) | 2001-12-06 |
NO20025762L (no) | 2003-01-09 |
NO20025762D0 (no) | 2002-11-29 |
DE60112924T2 (de) | 2006-03-16 |
US20030236252A1 (en) | 2003-12-25 |
EP1286975B1 (en) | 2005-08-24 |
AP2002002697A0 (en) | 2002-12-31 |
BG107375A (bg) | 2003-09-30 |
IL153170A0 (en) | 2003-06-24 |
HUP0302323A2 (hu) | 2003-10-28 |
IS6625A (is) | 2002-11-18 |
CA2409006A1 (en) | 2001-12-06 |
ATE302763T1 (de) | 2005-09-15 |
DE60112924D1 (de) | 2005-09-29 |
OA12275A (en) | 2003-12-11 |
EP1286975A1 (en) | 2003-03-05 |
MA26907A1 (fr) | 2004-12-20 |
ZA200209325B (en) | 2004-02-16 |
KR20030007797A (ko) | 2003-01-23 |
CN1438996A (zh) | 2003-08-27 |
US6794402B2 (en) | 2004-09-21 |
SK16632002A3 (sk) | 2003-08-05 |
EE200200667A (et) | 2004-06-15 |
MXPA02011926A (es) | 2003-04-22 |
JP2003535083A (ja) | 2003-11-25 |
HRP20021018A2 (en) | 2004-02-29 |
EA200201158A1 (ru) | 2003-04-24 |
WO2001092239A1 (en) | 2001-12-06 |
PL359260A1 (en) | 2004-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111301A (pt) | Cicloexilaminas bicìclicas e seu uso como antagonistas de receptor de nmda | |
BR0110247A (pt) | Derivado de ciclohexilamina como antagonistas de receptor de nmda seletivos em subtipo | |
BR0111267A (pt) | Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda | |
UY27222A1 (es) | Pirazolopirimidinas como agentes terapéuticos | |
ECSP034774A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
BRPI0113331B8 (pt) | derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica | |
BRPI0407741B8 (pt) | pirimidinas e triazinas de inibição de replicação de hiv | |
WO2004060882A8 (en) | Cb 1/cb 2 receptor ligands and their use in the treatment of pain | |
BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
ES2159738T3 (es) | Derivados de benzamida y su uso como antagonistas de vasopresina. | |
BR0111279A (pt) | Derivados da ciclohexilamina como antagonistas para o receptor do nmda seletivo ao subtipo | |
WO2001066534A3 (en) | Cyclic and bicyclic diamino histamine-3 receptor antagonists | |
BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
CY1106645T1 (el) | Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος | |
AR023966A1 (es) | Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion | |
UA85541C2 (ru) | Карбаматные производные хинуклидина и фармацевтическая композиции, которая содержит эти соединения | |
ATE225349T1 (de) | Crf rezeptor-antagonisten und darauf bezogene methoden | |
BR0113291A (pt) | steres de aporfina e seu uso em terapia | |
SE9802208D0 (sv) | Novel compounds | |
BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
BR0210912A (pt) | Compostos e composições como inibidores de catepsina | |
BRPI0410050A (pt) | método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto | |
BR9916887A (pt) | Uso de derivados de pirimidina | |
BR0116311A (pt) | Derivados de piperidina como subtipo de antagonistas de n-metil-d-aspartato selectivos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A, 9A E 10A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |